Drug Trial Radar · NCT07608432
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Dec 2030
Study completion Oct 2032
Sponsor
- Lead sponsor
- Dyne TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
Conditions
- Duchenne Muscular Dystrophy (DMD)
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy (DMD)
- DMD
- Muscular Dystrophies
- Muscular Dystrophy in Children
- Muscular Dystrophy, Duchenne Type
- Muscular Dystrophy, Duchenne and Becker Types
- Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
- Genetic Disease, Inborn
- Genetic Disease, X-Linked
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Neuromuscular Diseases (NMD)
Interventions
Zeleciment Rostudirsen (DYNE-251)Drug
Administered by IV infusion
PlaceboDrug
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rise From Floor (RFF) velocityTime frame: Baseline, Week 73
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rare Disease Research, LLC
Hillsborough, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.